Targeted modulation of complement activity to treat autoimmunity and cancer
| dc.rights.license | CC-BY-NC-ND | |
| dc.contributor.advisor | Rooijakkers, S.H.M. | |
| dc.contributor.author | Beek, Jeroen van | |
| dc.date.accessioned | 2023-03-02T01:01:49Z | |
| dc.date.available | 2023-03-02T01:01:49Z | |
| dc.date.issued | 2023 | |
| dc.identifier.uri | https://studenttheses.uu.nl/handle/20.500.12932/43596 | |
| dc.description.sponsorship | Utrecht University | |
| dc.language.iso | EN | |
| dc.subject | This article discusses the role of the complement system in autoimmune diseases and cancer. Antibody therapies are used to reduce complement activation or induce tumor cell cytotoxicity. However, complement-based therapeutics are costly and have side effects. This article explores targeted approaches in anti-autoimmunity drugs, including fusion proteins that target areas of inflammation or specific organs and bispecific antibodies, which can target complement regulatory proteins. | |
| dc.title | Targeted modulation of complement activity to treat autoimmunity and cancer | |
| dc.type.content | Master Thesis | |
| dc.rights.accessrights | Open Access | |
| dc.subject.courseuu | Drug Innovation | |
| dc.thesis.id | 14523 |